Kallebo Lisa Michelle 4

What Happened
Lisa Michelle Kallebo, Chief Accounting Officer of ADC Therapeutics (ADCT), received a grant of 62,900 restricted share units (RSUs) on February 13, 2026, valued at $3.99 per share (total ~$250,971). Simultaneously, 5,433 common shares were withheld by the company to satisfy tax withholding obligations at the same $3.99 per-share value (≈ $21,678). The RSU grant is reported under transaction code A (award); the withholding is reported under code F.

Key Details

• Transaction date: February 13, 2026. Grant/award price used: $3.99 per share.
• Award: 62,900 RSUs (value ≈ $250,971). Tax withholding: 5,433 shares withheld (value ≈ $21,678).
• Vesting: Footnote indicates the RSUs vest one-third on the first anniversary of the grant (Feb 13, 2027) and one-third on each anniversary thereafter, subject to continued service. (Footnote F1)
• Withholding: The 5,433 shares were withheld to satisfy tax obligations on prior RSU vesting (Footnote F2).
• Post-transaction share count: Not disclosed in the filing.
• Filing timeliness: Form 4 filed Feb 18, 2026 for Feb 13 transactions; filing appears to meet the two-business-day filing requirement (Feb 16, 2026 was a U.S. holiday).

Context
This was a compensation award (RSUs), not an open-market purchase or sale. RSU grants are common executive compensation and do not by themselves indicate a buying/selling market signal; they represent potential future shares subject to vesting. The tax-withholding step reduced the number of shares actually delivered to Ms. Kallebo when taxes were paid on vested units.